SCHEMBL14743412

SCHEMBL14743412

CC(Cc1cccs1)C(=O)N1CCC(O)(Cn2cnc3ccccc3c2=O)CC1

nearest known ligand 0.76

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
USP7 Q93009 15/20 0.76
USP19 O94966 2/20 0.51
ALDH1A1 P00352 1/20 0.49
GAA P10253 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14735378 0.89 USP7 (0.62) USP7USP19
SCHEMBL14735440 0.86 USP7 (1.00) USP7USP19
SCHEMBL14744124 0.84 USP7 (0.78) USP7USP19
SCHEMBL14735503 0.83 USP7 (0.65) USP7ALDH1A1GAA
SCHEMBL16303296 0.81 USP7 (0.73) USP7USP19
SCHEMBL17937970 0.80 USP7 (0.85) USP7USP19
SCHEMBL17937962 0.78 USP7 (0.50) USP7ALDH1A1GAA
SCHEMBL14746402 0.78 USP7 (0.48) USP7USP19ALDH1A1
SCHEMBL14746404 0.78 USP7 (0.48) USP7USP19ALDH1A1GAA
SCHEMBL26036532 0.77 USP7 (0.82) USP7USP19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9546150-B2 Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7 HYBRIGENICS SA (FR) 2017-01-17 US disclosed
US-9546150-B2 Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7 HYBRIGENICS SA (FR) 2017-01-17 US disclosed
US-9546150-B2 Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7 HYBRIGENICS SA (FR) 2017-01-17 US disclosed
EP-2751092-B1 SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 HYBRIGENICS SA (FR) 2016-07-27 EP disclosed
EP-2751092-B1 SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 HYBRIGENICS SA (FR) 2016-07-27 EP disclosed
US-20140371247-A1 Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7 HYBRIGENICS SA (FR) 2014-12-18 US disclosed
US-20140371247-A1 Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7 HYBRIGENICS SA (FR) 2014-12-18 US disclosed
US-20140371247-A1 Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7 HYBRIGENICS SA (FR) 2014-12-18 US disclosed
EP-2751092-A1 SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 Hybrigenics S.A. (FR) 2014-07-09 EP disclosed
WO-2013030218-A1 SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 HYBRIGENICS SA (FR) 2013-03-07 WO disclosed
WO-2013030218-A1 SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 HYBRIGENICS SA (FR) 2013-03-07 WO disclosed
EP-2565186-A1 Selective and reversible inhibitors of ubiquitin specific protease 7 Hybrigenics S.A. (FR) 2013-03-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371247-A1 Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7 USP7, UBA7, SENP7 USP7 1/4885USP19 20/4885ALDH1A1 1935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.